⌘K
Loading ticker…
As of 2026-08-25, iBio, Inc. Common Stock (IBIO) has a 3-month relative strength percentile of 21 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 52. The current market Stance is 52.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.7%, relative volume 0.57×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
IBIO is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $1M notional.
Held by 2 ETFs · $2M across latest filings · largest weight 0.00% (VXF).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $1M | — |
| VXFVanguard Extended Market ETF | 0.00% | $753K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IBIO Jan avg: 19.60% median: 15.83% win: 75% σ: 34.16% n: 4 2022-04-12 → 2026-07-31 | IBIO Feb avg: 53.71% median: 54.81% win: 100% σ: 37.53% n: 4 2022-04-12 → 2026-07-31 | IBIO Mar avg: 55.26% median: 15.73% win: 50% σ: 119.86% n: 4 2022-04-12 → 2026-07-31 | IBIO Apr avg: -45.09% median: -48.08% win: 0% σ: 23.72% n: 5 2022-04-12 → 2026-07-31 | IBIO May avg: -5.71% median: -17.64% win: 40% σ: 30.92% n: 5 2022-04-12 → 2026-07-31 | IBIO Jun avg: -4.69% median: -7.90% win: 20% σ: 9.20% n: 5 2022-04-12 → 2026-07-31 | IBIO Jul avg: -12.94% median: -13.45% win: 0% σ: 6.65% n: 5 2022-04-12 → 2026-07-31 | IBIO Aug avg: -0.57% median: 8.17% win: 50% σ: 28.74% n: 4 2022-04-12 → 2026-07-31 (current) | IBIO Sep avg: -6.04% median: 0.87% win: 75% σ: 22.40% n: 4 2022-04-12 → 2026-07-31 | IBIO Oct avg: 12.00% median: 1.63% win: 50% σ: 60.39% n: 4 2022-04-12 → 2026-07-31 | IBIO Nov avg: -19.27% median: -26.40% win: 25% σ: 22.66% n: 4 2022-04-12 → 2026-07-31 | IBIO Dec avg: -22.25% median: -37.39% win: 25% σ: 57.66% n: 4 2022-04-12 → 2026-07-31 |